These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 34480761)
1. A paradoxical head and neck erythema: an adverse event due to dupilumab in adult patients with atopic dermatitis. Russo F; Rizzo A; Santi F; Lamberti A; Lazzeri L; Flori ML; Rubegni P Int J Dermatol; 2022 Jun; 61(6):e204-e206. PubMed ID: 34480761 [No Abstract] [Full Text] [Related]
2. Dupilumab facial redness: Clinical characteristics and proposed treatment in a cohort. Ordóñez-Rubiano MF; Casas M; Balaguera-Orjuela V Dermatol Ther; 2021 Nov; 34(6):e15140. PubMed ID: 34549488 [TBL] [Abstract][Full Text] [Related]
3. Clinical and histopathological characterization of paradoxical head and neck erythema in patients with atopic dermatitis treated with dupilumab: a case series. de Wijs LEM; Nguyen NT; Kunkeler ACM; Nijsten T; Damman J; Hijnen DJ Br J Dermatol; 2020 Oct; 183(4):745-749. PubMed ID: 31749159 [TBL] [Abstract][Full Text] [Related]
5. Facial and neck erythema associated with dupilumab treatment: A systematic review. Jo CE; Finstad A; Georgakopoulos JR; Piguet V; Yeung J; Drucker AM J Am Acad Dermatol; 2021 May; 84(5):1339-1347. PubMed ID: 33428978 [TBL] [Abstract][Full Text] [Related]
6. Paradoxical Head and Neck Erythema in Patients Treated With Dupilumab: Not Only Red Face. Russo F; Sordi D; Madonna S; Dattolo A; Scala E; Pilla MA; Pallotta S; Giampetruzzi AR; De Pità O; Cocuroccia B Dermatitis; 2024; 35(4):421-423. PubMed ID: 38484334 [No Abstract] [Full Text] [Related]
7. Angioedema: A potential complication of dupilumab in atopic dermatitis. Fritz AL; Lacy FA; Morrell DS Pediatr Dermatol; 2021 Jan; 38(1):237-238. PubMed ID: 33099796 [TBL] [Abstract][Full Text] [Related]
8. Diffuse erythema and peeling during dupilumab therapy in a patient with atopic dermatitis. Cheng B; Yin M; Dou X Dermatol Ther; 2021 Nov; 34(6):e15183. PubMed ID: 34716650 [No Abstract] [Full Text] [Related]
9. Two differing presentations of periocular dermatitis as a side effect of dupilumab for atopic dermatitis. Yamane MLM; Belsito DV; Glass LRD Orbit; 2019 Oct; 38(5):390-394. PubMed ID: 30628518 [TBL] [Abstract][Full Text] [Related]
10. Dupilumab for children and adolescents with atopic dermatitis: An Asian perspective. Chia SY; Wee LWY; Koh MJA Dermatol Ther; 2021 May; 34(3):e14933. PubMed ID: 33751751 [TBL] [Abstract][Full Text] [Related]
11. New-onset head and neck dermatitis in adolescent patients after dupilumab therapy for atopic dermatitis. Bax CE; Khurana MC; Treat JR; Castelo-Soccio L; Rubin AI; McMahon PJ Pediatr Dermatol; 2021 Mar; 38(2):390-394. PubMed ID: 33426747 [TBL] [Abstract][Full Text] [Related]
12. Facial erythema in patients with atopic dermatitis treated with Dupilumab - a descriptive study of morphology and Aetiology. Ahn J; Lee DH; Na CH; Shim DH; Choi YS; Jung HJ; Simpson EL J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):2140-2152. PubMed ID: 35695074 [TBL] [Abstract][Full Text] [Related]
13. Weight gain in patients with severe atopic dermatitis treated with dupilumab: a cohort study. Johansson EK; Ivert LU; Bradley B; Lundqvist M; Bradley M BMC Dermatol; 2020 Sep; 20(1):8. PubMed ID: 32962676 [TBL] [Abstract][Full Text] [Related]
14. Difference in the rate of ocular adverse events with dupilumab between asthma and atopic dermatitis patients. Wang Y; Jorizzo J Int J Dermatol; 2021 Sep; 60(9):e382. PubMed ID: 33715168 [No Abstract] [Full Text] [Related]
15. Dupilumab facial redness: histologic characterization on a series of four cases. Dybała A; Sernicola A; Gomes V; Carnicelli G; Muharremi R; Grieco T Immunotherapy; 2022 Mar; 14(4):183-188. PubMed ID: 34933583 [TBL] [Abstract][Full Text] [Related]
16. Dupilumab ocular surface disease occurs predominantly in patients receiving dupilumab for atopic dermatitis: A multi-institution retrospective chart review. Waldman RA; DeWane ME; Sloan SB; King B; Grant-Kels JM J Am Acad Dermatol; 2021 Sep; 85(3):735-736. PubMed ID: 31325553 [No Abstract] [Full Text] [Related]
17. Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis. Halling AS; Loft N; Silverberg JI; Guttman-Yassky E; Thyssen JP J Am Acad Dermatol; 2021 Jan; 84(1):139-147. PubMed ID: 32822798 [TBL] [Abstract][Full Text] [Related]
18. Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry. Bosma AL; de Wijs LEM; Hof MH; van Nieuwenhuizen BR; Gerbens LAA; Middelkamp-Hup MA; Hijnen D; Spuls PI J Am Acad Dermatol; 2020 Nov; 83(5):1375-1384. PubMed ID: 32485210 [TBL] [Abstract][Full Text] [Related]
19. Dupilumab-induced serum sickness-like reaction: an unusual adverse effect in a patient with atopic eczema. Treudler R; Delaroque N; Puder M; Simon JC; Szardenings M J Eur Acad Dermatol Venereol; 2021 Jan; 35(1):e30-e32. PubMed ID: 32594596 [No Abstract] [Full Text] [Related]
20. Immune Thrombocytopenic Purpura in a Patient with Atopic Dermatitis Treated with Dupilumab. Frey S; Kendziora B; Holch JW; Lindner L; French LE; Wollenberg A Acta Derm Venereol; 2021 Mar; 101(3):adv00409. PubMed ID: 33349889 [No Abstract] [Full Text] [Related] [Next] [New Search]